2023-508127-13-00已完成2 期
A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
Novartis Pharma AG, Novartis Pharma AG12 个研究点 分布在 7 个国家目标入组 41 人开始时间: 2024年2月5日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
- 试验地点
- 12
- 主要终点
- 1. Complete response rate (CRR) determined by an Independent Review Committee (IRC) in the efficacy analysis set (EAS) based on Lugano 2014 classification response criteria (Cheson et al 2014).
研究概览
简要总结
Evaluate the efficacy of tisagenlecleucel therapy as measured by CRR determined by IRC
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Written informed consent prior to any screening procedures
- •≥18 years of age at the time of ICF signature
- •FL (Grade 1, 2, 3A) confirmed histologically by central pathology review before tisagenlecleucel infusion.
- •FL meeting one of the following criteria: • Refractory to a second line or later line of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed within 6 months after completion of a second line or later line of systemic therapy • Relapsed during anti-CD20 antibody maintenance (following at least two lines of therapies as above) or within 6 months after maintenance completion • Relapsed after autologous HSCT
- •Radiographically measurable disease at screening defined as: • At least one nodal lesion greater than 20 mm in the long axis, regardless of the length of the short axis AND/OR • Extranodal lesions (outside lymph node or nodal mass, including liver and spleen) greater than 10 mm in long AND short axis
- •ECOG performance status that is either 0 or 1 at screening
- •Patients must meet the following laboratory values without transfusion at screening: • Absolute neutrophil count (ANC) ≥ 1,000/mm3 (≥ 1×109/L) • Absolute lymphocyte count (ALC) > 300/mm3 (> 0.3×109/L) • Absolute number of CD3+ T cells > 150/mm3 (> 0.15×109/L) • Platelets ≥ 50 000/mm3 (≥ 50×109/L) • Hemoglobin ≥ 8.0 g/dl (≥ 4.9 mmol/L) • A serum creatinine of ≤1.5 times ULN or eGFR ≥ 60 mL/min/1.73 m2 • Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST) ≤ 5 times the Upper Limit of Normal (ULN) • Total bilirubin (TBIL) ≤ 1.5 times ULN (with the exception of patients with Gilbert’s syndrome. Patients with Gilbert’s syndrome may be included if their total bilirubin is ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN
- •Adequate pulmonary function defined as: • No or mild dyspnea (≤ Grade 1) • Oxygen saturation measured by pulse oximetry > 90% on room air
- •Must have a leukapheresis product of non-mobilized cells accepted for manufacturing
排除标准
- •Evidence of histologic transformation
- •Presence of active or prior hepatitis B or C as indicated by serology. Serology must be repeated, if the interval between testing prior to lymphodepletion and tisagenlecleucel infusion exceeds 8 weeks
- •Presence of HIV antibody. Serology must be repeated, if the interval between testing prior to lymphodepletion and tisagenlecleucel infusion exceeds 8 weeks
- •Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to tisagenlecleucel infusion)
- •Cardiac or cardiac repolarization abnormality, including any of the following: • History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) • LVEF <45% as determined by ECHO or MRA or MUGA • NYHA functional class III or IV
- •Previous or concurrent malignancy with the following exceptions: a. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to enrollment) b. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to enrollment c. A primary malignancy which has been completely resected and in complete remission for ≥ 3 years at the time of enrollment
- •Pregnant or nursing (lactating) women NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 24 hours before leukapheresis, lymphodepletion and prior to tisagenlecleucel infusion.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for at least 12 months after the tisagenlecleucel infusion and until CAR T-cells are no longer present by qPCR on two consecutive tests. Highly effective contraception methods include: • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment • Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
- •Sexually active males must use a condom during intercourse while taking study treatment and for at least 12 months after the tisagenlecleucel infusion and until CAR T-cells are no longer present by qPCR on two consecutive tests. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above.
- •Intolerance to the excipients of the tisagenlecleucel cell product.
- •Follicular Lymphoma Grade 3B
- •Prior anti-CD19 therapy
- •Prior gene therapy
- •Prior adoptive T cell therapy
- •Prior allogeneic hematopoietic stem cell transplant
- •Active CNS involvement by malignancy
- •Active neurological autoimmune or inflammatory disorders (e.g. Guillain-Barre syndrome, Amyotrophic Lateral Sclerosis)
- •Investigational medicinal product within the last 30 days or five half-lives (whichever is longer) prior to screening
结局指标
主要结局
1. Complete response rate (CRR) determined by an Independent Review Committee (IRC) in the efficacy analysis set (EAS) based on Lugano 2014 classification response criteria (Cheson et al 2014).
1. Complete response rate (CRR) determined by an Independent Review Committee (IRC) in the efficacy analysis set (EAS) based on Lugano 2014 classification response criteria (Cheson et al 2014).
次要结局
- ORR, including complete response (CR) and partial response (PR) determined by IRC in the FAS based on Lugano 2014 classification. DOR, defined as time from CR/PR to relapse or death due to FL, based on IRC DOR for CR only, defined as time from CR to relapse or death due to FL, based on IRC. PFS, defined as time from tisagenlecleucel infusion to first documented disease progression or death due to any cause, based on IRC.OS, defined as time from tisagenlecleucel infusion to death due to any cause
- Type, frequency and severity of adverse events and laboratory abnormalities
- Summary of: -qPCR detected tisagenlecleucel transgene concentrations in peripheral blood, bone marrow and other tissues by time point and clinical response status. -cellular kinetic parameters: Cmax, Tmax, AUC0-28 and AUC0-84d, T1/2, and/or other relevant parameters in peripheral blood; bone marrow and other tissues by clinical response as appropriate -exposure and cellular kinetic parameters of CD3+ tisagenlecleucel cells in peripheral blood detected by flow cytometry
- Summary of pre-existing and treatment induced immunogenicity (cellular and humoral) of tisagenlecleucel
- Levels of pre-existing and treatment induced immunogenicity Cellular kinetic parameters (Cmax, AUCs, Tlast), concentration-time profile tisagenlecleucel by immunogenicity category (positive/negative) Efficacy (ORR, DOR, PFS) Safety (B-cell levels, CRS grades, neurologic events)
- Summary scores of PRO measured by SF-36 version 2, EQ-5D-3L and FACT-Lym quality of life questionnaires
研究者
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
研究点 (12)
Loading locations...
相似试验
招募中
2 期
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma2025-522054-40-00Iovance Biotherapeutics Inc.69
招募中
2 期
An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the therapy of newly diagnosed high -risk multiple myelomaMultiple Myeloma2024-514016-26-00Fundacion Pethema30
招募中
4 期
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic TherapyPlaque Psoriasis2023-509738-20-00AbbVie Deutschland GmbH & Co. KG150
招募中
3 期
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011)2024-516834-36-00Merck Sharp & Dohme LLC189
招募中
2 期
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis2024-517356-35-00Citryll B.V.77